CEO of Recce Pharmaceuticals
Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327
January 11th 2024With gonorrhea's rising antibiotic resistance, Recce 327 by Recce Pharmaceuticals emerges as a game-changer, showing 99% efficacy in preclinical trials and promising potential against antibiotic-resistant bacteria globally.